Drug-resistant bacteria are draining the global economy — fast. A new study presented at IDWeek found that antimicrobial resistance (AMR) caused nearly $1 trillion in welfare losses in 2021 alone, driven largely by bloodstream and respiratory infections. Researchers warn that no country is safe, and with 39 million projected deaths by 2050, the financial and human toll is only set to grow.
Drug-resistant bacteria don't carry passports — and neither do their costs. A study presented at IDWeek 2026 applied the Value of Lost Welfare (VLW) framework to quantify the global economic toll of antimicrobial resistance (AMR) in 2021, revealing a staggering near-trillion-dollar loss. Researchers linked AMR-attributable disability-adjusted life-years (DALYs) across 12 infectious syndromes and 22 bacterial pathogens to country-level data worldwide.
Bloodstream and lower respiratory infections were the biggest cost drivers, fueled primarily by six pathogens: Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. While South Asia, East Asia, and North America bore the greatest absolute losses, sub-Saharan Africa felt the deepest hit relative to GDP — underscoring how poorer regions pay a disproportionate price.
By the Numbers:
Why it matters: AMR is not just a clinical crisis — it's an economic one. These findings reframe the conversation for policymakers and budget makers, making the case that investing in antibiotic stewardship and new treatments isn't just a health priority, it's a financial imperative for every nation.
